Modafinil, d-amphetamine and placebo during 64 hours of sustained mental work .2. Effects on two nights of recovery sleep
Modafinil, d-amphetamine and placebo during 64 hours of sustained mental work .2. Effects on two nights of recovery sleep
复制标题
DOI：
10.1111/j.1365-2869.1995.tb00173.x
复制
发表时间：
1995-12-01
影响因子：
4.4
通讯作者：
Naitoh, P
中科院分区：
文献类型：
--
作者：
Buguet, A;Montmayeur, A;Naitoh, P
多导睡眠图从37名志愿者，之前（基线）和之后（连续两个恢复夜）64小时睡眠剥夺，（d-苯丙胺或莫达非尼）或（安慰剂）报警物质。药物在第一个睡眠剥夺夜的23：00给药（清醒17.5小时后），以确定是否可以防止认知能力的下降;在睡眠剥夺的第二个晚上的05.30小时（47.5小时清醒后），看看是否会恢复性能;并在连续工作的第三天的15.30小时，研究对恢复睡眠的影响。第二个恢复之夜用于验证第一个恢复之夜药物诱导的睡眠障碍是否会延续到第二个睡眠之夜。安慰剂组的恢复睡眠与预期一致：慢波睡眠（SWS）和REM睡眠的债务在第一个恢复夜晚得到偿还，SWS的反弹主要发生在前半夜，REM睡眠的反弹在REM睡眠中均匀分布。安非他明组的恢复睡眠也与以前发表的工作一致：增加睡眠潜伏期和睡眠内觉醒，减少总睡眠时间和睡眠效率，改变阶段转移，阶段1，阶段2和SWS，减少REM睡眠，REM睡眠潜伏期更长。对于这一组，仅在第二个恢复之夜观察到REM睡眠反弹。莫达非尼组的结果显示卧床时间和睡眠时间减少，表明恢复睡眠的需求比其他两组减少。在第一个恢复之夜，这一组比安非他明组表现出更少的干扰。特别是，没有REM睡眠不足，REM睡眠发作较长，REM潜伏期较短，REM睡眠反弹仅限于第一次REM睡眠发作。与安非他明组的差异也是由较少的NREM睡眠和第二阶段和更多的SWS发作。在第二个恢复之夜没有发生REM睡眠反弹，这与安慰剂几乎没有区别。因此，莫达非尼允许睡眠发生，显示出与安慰剂组接近的睡眠模式，并减少了对长时间恢复睡眠的需要，这种恢复睡眠通常用于补偿由于完全睡眠剥夺而失去的睡眠。
Polysomnograms were obtained from 37 volunteers, before (baseline) and after (two consecutive recovery nights) a 64-h sleep deprivation, with (d-amphetamine or modafinil) or without (placebo) alerting substances. The drugs were administered at 23.00 hours during the first sleep deprivation night (after 17.5 h of wakefulness), to determine whether decrements in cognitive performance would be prevented; at 05.30 hours during the second night of sleep deprivation (after 47.5 h of wakefulness), to see whether performance would be restored; and at 15.30 hours during the third day of continuous work, to study effects on recovery sleep. The second recovery night served to verify whether drug-induced sleep disturbances on the first recovery night would carry over to a second night of sleep. Recovery sleep for the placebo group was as expected: the debt in slow-wave sleep (SWS) and REM sleep was paid back during the first recovery night, the rebound in SWS occurring mainly during the first half of the night, and that of REM sleep being distributed evenly across REM sleep episodes. Recovery sleep for the amphetamine group was also consistent with previously published work: increased sleep latency and intrasleep wakefulness, decreased total sleep time and sleep efficiency, alterations in stage shifts, Stage 1, Stage 2 and SWS, and decreased REM sleep with a longer REM sleep latency. For this group, REM sleep rebound was observed only during the second recovery night. Results for the modafinil group exhibited decreased time in bed and sleep period time, suggesting a reduced requirement for recovery sleep than for the other two groups. This group showed fewer disturbances during the first recovery night than the amphetamine group. In particular, there was no REM sleep deficit, with longer REM sleep episodes and a shorter REM latency, and the REM sleep rebound was limited to the first REM sleep episode. The difference with the amphetamine group was also marked by less NREM sleep and Stage 2 and more SWS episodes. No REM sleep rebound occurred during the second recovery night, which barely differed from placebo. Hence, modafinil allowed for sleep to occur, displayed sleep patterns close to that of the placebo group, and decreased the need for a long recovery sleep usually taken to compensate for the lost sleep due to total sleep deprivation.